Treating female heart failure patients with metoprolol CR/XL

Jalal K. Ghali, Ileana L. Piña, Stephen S. Gottlieb, Prakash C. Deedwania, John C. Wikstrand

Research output: Contribution to journalArticle

Abstract

We examined the effect of metoprolol controlled release/extended release (CR/XL) in 898 female patients participating in the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure. There was a 21 reduction in the primary end points of total mortality and all-cause hospitalization. There was also a decrease in all-cause (15%), cardiovascular-cause (29%), and heart-failure hospitalization (42%). These data show the therapeutic benefit of beta blocking agents in women with heart failure.

Original languageEnglish (US)
Pages (from-to)29-32
Number of pages4
JournalCardiology Review
Volume19
Issue number12
StatePublished - Oct 1 2002

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Treating female heart failure patients with metoprolol CR/XL'. Together they form a unique fingerprint.

  • Cite this

    Ghali, J. K., Piña, I. L., Gottlieb, S. S., Deedwania, P. C., & Wikstrand, J. C. (2002). Treating female heart failure patients with metoprolol CR/XL. Cardiology Review, 19(12), 29-32.